Digestive Diseases and Sciences

, Volume 41, Supplement 12, pp 75S–80S | Cite as

Health assessment for chronic HCV infection

Results of quality of life
  • Robert L. CarithersJr.
  • David Sugano
  • Martha Bayliss
Article

Abstract

The perception that chronic hepatitis C is an asymptomatic disease contrasts with many studies that show a strong association between chronic hepatitis C, hepatocellular cancer, and fatal liver disease. In order to resolve these issues, it is logical to directly evaluate the quality of life in patients with chronic hepatitis C and to compare this to the normal population as well as cohorts of patients with other chronic diseases. The Sickness Impact Profile was used to evaluate the impact of disease and interferon therapy on health-related quality of life in patients with chronic hepatitis C. Using this tool, patients with chronic hepatitis C had a total Sickness Impact Profile score of 9.0, compared with a score of 3.6 among the general population (P<0.05). Patients with chronic hepatitis C also had significantly worse scores in almost every category of the Sickness Impact Profile that could be compared. However, statistically significant differences were observed only at the 24-week evaluation for work and at the end-point evaluation for the sleep and rest and recreation and pastimes categories. A more sophisticated instrument, based on the Medical Outcomes Study 36-item short-form health survey, found that patients with chronic hepatitis C scored significantly lower (P<0.01) than the general population on each of the subscales in this survey. In addition, they scored significantly lower than patients with hypertension in seven of the subscales and two additional generic scales. Patients with chronic hepatitis C were most comparable to those with type II diabetes. A larger, more comprehensive study is underway to further evaluate these relationships.

Key words

hepatitis C virus chronic infection quality of life measures 

References

  1. 1.
    Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger BF, Gitnick G, Knodell RG, Perillo PP, Stevens CE, Hollingsworth CDG, and the National Heart, Lung, and Blood Institute Study Group: Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 327:1906–1911, 1992Google Scholar
  2. 2.
    Kiyosawa K, Akahane Y, Nagata A, Koike Y, Furuta S: The significance of blood transfusion in non-A, non-B chronic liver disease in Japan. Vox Sang 43:45–52, 1982Google Scholar
  3. 3.
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Martino FP, Sangvhi B, Albrecht JK: Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther 16:334–343, 1994Google Scholar
  4. 4.
    Bergner M, Bobbitt RA, Carter WB, Gilson BS: The sickness impact profile: Development and final revision of a health status measure. Med Care 19:787–805, 1981Google Scholar
  5. 5.
    de Bruin AF, de Witte LP, Stevens F, Diederiks JPM: Sickness impact profile: The state of the art of a generic functional status measure. Soc Sci Med 35:1003–1014, 1992Google Scholar
  6. 6.
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, and the Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 321:1501–1506, 1989Google Scholar
  7. 7.
    Schuling J, Greidanus J, Meyboom-de Jong B: Measuring functional status of stroke patients with the sickness impact profile. Disabil Rehabil 15:19–23, 1993Google Scholar
  8. 8.
    Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483, 1992Google Scholar
  9. 9.
    McHorney CA, Ware JE, Raczek AE: The MOS 36-item short-form health status survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–263, 1993Google Scholar
  10. 10.
    McHorney CA, Ware JE, Lu JFR, Sherbourne CD: The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 32:40–66, 1994Google Scholar
  11. 11.
    Hays RD, Stewart AL: Sleep measures.In Measuring Function and Well-Being: The Medical Outcomes Study Approach. AL Stewart, JE Ware (eds). Durham, North Carolina, Duke University Press, 1992, pp 235–259Google Scholar
  12. 12.
    Stewart AL, Ware JE, Sherbourne CD, Wells KB: Psychological distress/well-being and cognitive functioning measures.In Measuring Function and Well-Being: The Medical Outcomes Study Approach. AL Stewart, JE Ware (eds). Durham, North Carolina, Duke University Press, 1992, pp 102–142Google Scholar
  13. 13.
    Stewart AL, Hays RD, Ware JE: Health perceptions, energy/fatigue and health distress measures.In Measuring Function and Well-Being: The Medical Outcomes Study Approach. AL Stewart, JE Ware (eds). Durham, North Carolina, Duke University Press, 1992, pp 143–172Google Scholar
  14. 14.
    Stewart AL, Ware JE (eds): Measuring Function and Well-Being: The Medical Outcomes Study Approach. Durham, North Carolina, Duke University Press, 1992Google Scholar
  15. 15.
    Bayliss MS, Gandek B, Bungay KM, Hsu M-A, Ware JE: A questionnaire to assess the functional health and well-being of patients with chronic hepatitis C. J Clin Epidemiol (submitted)Google Scholar
  16. 16.
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435, 1981Google Scholar
  17. 17.
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513–1520, 1994Google Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Robert L. CarithersJr.
    • 3
    • 1
    • 2
  • David Sugano
    • 3
    • 1
    • 2
  • Martha Bayliss
    • 3
    • 1
    • 2
  1. 1.Pharmacoeconomics and QOL Research UnitSchering-Plough CorporationKenilworth
  2. 2.Division of Health Improvement, the Health InstituteNew England Medical CenterBoston
  3. 3.Hepatology Division, Department of MedicineUniversity of Washington Medical CenterSeattleUSA

Personalised recommendations